Form 4 Filing for Atara Biotherapeutics, Inc. - Officer/Director Transaction

Brian Cherry, a director at Atara Biotherapeutics, Inc., acquired 24,000 shares of common stock on June 11, 2026. This acquisition was made under a restricted stock unit award, with the shares vesting over three years, subject to continuous service. The shares were acquired at a price of $0.0 per share, and following this transaction, Mr. Cherry owns 62,320 shares of common stock directly. The filing, designated as Form 4, was signed on June 15, 2026, by John Chao as attorney-in-fact for Brian Cherry. This transaction is classified as an equity transaction due to the nature of restricted stock units. The reporting owner is identified by CIK 0001290922.